MET Exon 14-altered Lung Cancers and MET Inhibitor Resistance.
Robin GuoMichael D OffinA Rose BrannonJason ChangAndrew ChowLukas DelasosJeffrey GirshmanOlivia WilkinsCaroline G McCarthyAlex MakhninChristina FalconKerry ScottYuan TianFabiola CecchiTodd HembroughDeepu AlexRonglai ShenRyma BenayedBob T LiCharles M RudinMark G KrisMaria E ArcilaNatasha RekhtmanPaul PaikAhmet ZehirAlexander E DrilonPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
In MET exon 14-altered cancers treated with a MET TKI, a comprehensive analysis of previously unknown and known genomic factors did not identify a genomic mechanism of primary resistance. Instead, MET expression correlated with benefit, suggesting the potential role of interrogating the proteome in addition to the genome in confirmatory prospective trials.